Miralax and Synagis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Miralax (polyethylene glycol 3350) and Synagis (palivizumab). Common drug interactions include seizure among females and respiratory syncytial virus infection among males.

The phase IV clinical study analyzes what interactions people have when they take Miralax and Synagis. It is created by eHealthMe based on reports of 57 people who take the same drugs from the FDA, and is updated regularly.

What is Miralax?

Miralax has active ingredients of polyethylene glycol 3350. It is often used in constipation. eHealthMe is studying from 81,754 Miralax users. Check the latest studies of Miralax.

What is Synagis?

Synagis has active ingredients of palivizumab. eHealthMe is studying from 19,114 Synagis users. Check the latest studies of Synagis.

On Jul, 30, 2026

57 people who take Miralax and Synagis together, and have interactions are studied.

What are the common drug interactions of Miralax and Synagis, by gender? *:

female:

Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Nasopharyngitis (inflammation of the nasopharynx)
Ear infection
Rash
Injection site erythema (redness at injection site)
Injection site reaction
Pyrexia (fever)
Respiratory distress (difficulty in breathing)
Bronchopulmonary dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type)
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)

male:

Respiratory syncytial virus infection (viral disease of respiratory system)
Pyrexia (fever)
Injection site erythema (redness at injection site)
Nasopharyngitis (inflammation of the nasopharynx)
Rash
Respiratory syncytial virus test positive
Unresponsive to stimuli
Polycythaemia (proportion of blood volume that is occupied by red blood cells increases)
Swelling
Abdominal mass (localized enlargement or swelling in the human abdomen)

What are the common drug interactions of Miralax and Synagis, by age (0-1 to 60+)? *:

0-1:

Injection site erythema (redness at injection site)
Ear infection
Nasopharyngitis (inflammation of the nasopharynx)
Respiratory syncytial virus test positive
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Unresponsive to stimuli
Vomiting
Injection site reaction
Abdominal mass (localized enlargement or swelling in the human abdomen)
Bronchopulmonary dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type)

2-9:

Hospitalisation
Respiratory syncytial virus infection (viral disease of respiratory system)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Malaise (a feeling of general discomfort or uneasiness)
Upper respiratory tract infection

10-19:

Respiratory syncytial virus infection (viral disease of respiratory system)

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Premature Baby: 12 people, 21.05%
Respiratory Syncytial Virus Infection (viral disease of respiratory system): 6 people, 10.53%
Infantile Spasms: 5 people, 8.77%
Chronic Respiratory Failure: 3 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Miralax and Synagis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously